Why Gene Silencing Could Change Polycythemia Vera Treatment
August 20, 2026
In the phase 2 SANRECO trial, 88% of patients with polycythemia vera kept hematocrit below 45% without a phlebotomy. Lead investigator Dr. Marina Kremyanskaya explains what that could mean day to day.
